Wuxi Griffin will be western-managed but located in China.
China-based Wuxi Fortune Pharmaceutical and Sweden-based sterile filling and medical device validation and production company, SialoCarb, have formed Wuxi Griffin Pharmaceutical, a new contract manufacturer focused on the aseptic fill and finish of sterile pharmaceuticals.
The company will be headed by Torgny Lundgren. Wuxi Griffin will manufacture monoclonal antibodies, vaccines, vaccine, recombinant proteins and biosimilars, as well as traditional small-molecule drugs. The 7,450-ft2 aseptic fill/finish facility includes restricted access barrier (RABS) and isolator technologies and has equipment for the production of both clinical and commercial material.
"Complying to global GMP gives us an advantage, as the requirements of Chinese customers wanting Western quality products are met. We also assist Western pharmaceutical companies wanting accelerated access to the Chinese market," said Lundgren.